Economic information and modeling reportBudget impact model
Budget impact model discussion
3 evidence topics · 12 sources
Summary
Task force good-practice guidance on budget impact analysis lists the key elements of a budget impact analysis as the size of the eligible population, the current and expected treatment mix, the cost of each mix, and changes in condition-related costs, and recommends the perspective of the specific decision maker, data from the decision maker's own population where possible, and presentation as a series of scenario analyses. For ficerafusp alfa, two inputs are not yet available: a price, and efficacy from randomized evidence. Results reported to date come from a nonrandomized, open-label phase 1/1b trial, and Bicara expects an interim analysis of the randomized FORTIFI-HN01 trial in mid-2027.
The population inputs in this report differ by source and are candidates for scenario ranges. The estimated HPV-negative share of recurrent or metastatic disease is 80% in Bicara's Form 10-K; in a U.S. real-world first-line cohort, 60.4% had non-HPV associated disease and 7.0% had unknown HPV status or primary site, and in a U.S. real-world cohort of first-line pembrolizumab recipients, 258 participants (39.9%) were HPV-negative and 155 (24.0%) equivocal or unknown. Bicara states that up to 30% of patients develop a recurrence or metastases after initial treatment for advanced HNSCC; Hanna et al. (2026) state that approximately 50% of those with locally advanced HNSCC have recurrence or metastasis after initial therapy; of 2,207 U.S. participants, 32.7%. Because the pivotal population requires PD-L1 CPS ≥1, testing rates bear on the identifiable population: of 2,207 U.S. participants, 32.7% received PD-L1 testing before first-line therapy and 50.0% were never tested.
On costs, pembrolizumab is given in both arms of FORTIFI-HN01, and ficerafusp alfa is given weekly until disease progression or unacceptable toxicity, while pembrolizumab is given for up to 35 cycles. FORTIFI-FLEX is evaluating a 12-week loading phase of 1500 mg weekly followed by 2250 mg every 3 weeks, which would change the number of administrations if adopted. Bicara states that third-party payers “may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available.”
Company statements on pricing, coverage, and reimbursement of ficerafusp alfa
Data sources recommended for budget impact inputs
“Data sources for the BIA should include published clinical trial estimates and comparator studies for the efficacy and safety of the current and new interventions as well as the decision maker's own population for the other parameter estimates, where possible.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote